This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

14 Aug 2017

Fortress Biotech forms new subsidiary, Aevitas Therapeutics

Subsidiary to develop novel AAV gene therapy treatments for complement-mediated.

Fortress Biotech has formed a new subsidiary company, Aevitas Therapeutics, to develop novel gene therapy approaches for complement-mediated diseases. The proprietary technology, licensed from a leading university, uses adeno-associated virus (AAV)-based gene therapy to restore lasting production of functional complement regulatory proteins, providing a potentially curative treatment.

Irregularities in these proteins can play a vital role in an array of complement-mediated diseases, including atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Recent research has suggested that complement regulatory proteins could also play a key role in the pathogenesis of age-related macular degeneration.

Dr Lindsay A. Rosenwald, Fortress Biotech’s Chairman, President and Chief Executive Officer, said: “We are thrilled to work on this potentially groundbreaking technology in numerous areas of unmet need as we continue to establish our capabilities in the gene therapy space.”

Related News